AbCellera Biologics (ABCL) Net Cash Flow (2020 - 2025)
AbCellera Biologics' Net Cash Flow history spans 6 years, with the latest figure at $44.5 million for Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 39.77% year-over-year to $44.5 million, compared with a TTM value of -$29.5 million through Dec 2025, down 214.99%, and an annual FY2025 reading of -$29.5 million, down 214.99% over the prior year.
- Net Cash Flow for Q4 2025 was $44.5 million at AbCellera Biologics, up from -$8.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $247.0 million in Q2 2022, with the low at -$408.8 million in Q3 2022.
- Average Net Cash Flow over 5 years is -$21.3 million, with a median of -$7.5 million recorded in 2023.
- Biggest YoY gain for Net Cash Flow was 342.17% in 2021; the steepest drop was 1145.28% in 2021.
- Tracing ABCL's Net Cash Flow over 5 years: stood at -$16.0 million in 2021, then skyrocketed by 188.59% to $14.2 million in 2022, then tumbled by 382.92% to -$40.2 million in 2023, then skyrocketed by 179.28% to $31.8 million in 2024, then soared by 39.77% to $44.5 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Net Cash Flow are $44.5 million (Q4 2025), -$8.7 million (Q3 2025), and -$67.6 million (Q2 2025).